



FORTIS MOHALI-CHC -SPLZD FORTIS HOSPITAL # MOHALI,

MOHALI 160062 7087030817 ACCESSION NO: **0006WE011801**PATIENT ID: FH.11716120
CLIENT PATIENT ID: UID:11716120

ABHA NO

AGE/SEX :33 Years Male
DRAWN :13/05/2023 09:46:00
RECEIVED :13/05/2023 13:53:25
REPORTED :13/05/2023 16:18:37

CLINICAL INFORMATION:

UID:11716120 REQNO-1521799

CORP-OPD

BILLNO-10021230PCS007376 BILLNO-10021230PCS007376

Test Report Status	Einal	Results	Biological Reference Interval	Unite
rest Report Status	<u>Final</u>	Results	Biological Reference Interval	Units

HAEMATOLOGY - CBC				
CBC-5, EDTA WHOLE BLOOD				
BLOOD COUNTS, EDTA WHOLE BLOOD				
HEMOGLOBIN (HB) METHOD: SLS- HEMOGLOBIN DETECTION METHOD	16.8	13.0 - 17.0	g/dL	
RED BLOOD CELL (RBC) COUNT METHOD: HYDRODYNAMIC FOCUSING	5.27	4.5 - 5.5	mil/μL	
WHITE BLOOD CELL (WBC) COUNT METHOD: FLOWCYTOMETRY	5.23	4.0 - 10.0	thou/μL	
PLATELET COUNT METHOD: HYDRO DYNAMIC FOCUSING METHOD / MICROSCOPY	179	150 - 410	thou/μL	
RBC AND PLATELET INDICES				
HEMATOCRIT (PCV)	50.2 High	40.0 - 50.0	%	
MEAN CORPUSCULAR VOLUME (MCV) METHOD: CALCULATED PARAMETER	95.3	83.0 - 101.0	fL	
MEAN CORPUSCULAR HEMOGLOBIN (MCH) METHOD: CALCULATED PARAMETER	31.9	27.0 - 32.0	pg	
MEAN CORPUSCULAR HEMOGLOBIN CONCENTRATION(MCHC) METHOD: CALCULATED PARAMETER	33.5	31.5 - 34.5	g/dL	
RED CELL DISTRIBUTION WIDTH (RDW) METHOD: CALCULATED PARAMETER	13.5	11.6 - 14.0	%	
MENTZER INDEX	18.1			
METHOD: CALCULATED PARAMETER MEAN PLATELET VOLUME (MPV) METHOD: CALCULATED PARAMETER	13.8 High	6.8 - 10.9	fL	

WBC DIFFERENTIAL COUNT

Ritu Pantay

Dr. Shafira Garg (MD, Pathology) Attending Consultant,47150

Dr. Meenakshi Malhotra, MD Senior Consultant,48159

Meenahahi Malhotra



Page 1 Of 20

View Details





Dr. Ritu Pankaj, MD, PDCC

Senior Consultant, 30897

CLINICAL LABORATORY Fortis Heart Institute & Multispeciality Hospital, Sector 62, Phase Viii,

Mohali, 160062 Punjab, India

Tel: 0172-469-2222 Extn. 6726, 6727), 0172-469-2221 - CIN -

L85110DL1996PLC076704 Email: srl.mohali@fortishealthcare.com Patient Ref. No. 6000003029242





FORTIS MOHALI-CHC -SPLZD FORTIS HOSPITAL # MOHALI,

MOHALI 160062 7087030817

ACCESSION NO : 0006WE011801 PATIENT ID : FH.11716120 CLIENT PATIENT ID: UID:11716120

ABHA NO

AGE/SEX :33 Years :13/05/2023 09:46:00 RECEIVED : 13/05/2023 13:53:25 REPORTED: 13/05/2023 16:18:37

CLINICAL INFORMATION:

UID:11716120 REQNO-1521799

CORP-OPD

BILLNO-10021230PCS007376 BILLNO-10021230PCS007376

BILLINO-10021230PC3007376				
Test Report Status	<u>Final</u>	Results	Biological Reference	e Interval Units
NEUTROPHILS		54	40.0 - 80.0	%
METHOD : FLOW CYTOMET	RY+LEISHMAIN STAIN+MICROSCOPY	,		
LYMPHOCYTES		36	20.0 - 40.0	%
METHOD : FLOW CYTOMET	RY+LEISHMAIN STAIN+MICROSCOPY	,		
MONOCYTES		7	2.0 - 10.0	%
METHOD : FLOW CYTOMET	RY+LEISHMAIN STAIN+MICROSCOPY	,		
EOSINOPHILS		3	1 - 6	%
METHOD : FLOW CYTOMET	RY+LEISHMAIN STAIN+MICROSCOPY	,		
BASOPHILS		00	0 - 2	%
METHOD : FLOW CYTOMET	RY+LEISHMAIN STAIN+MICROSCOPY	,		
ABSOLUTE NEUTRO	PHIL COUNT	2.82	2.0 - 7.0	thou/µL
METHOD: CALCULATED PA	RAMETER			
ABSOLUTE LYMPHO	CYTE COUNT	1.88	1.0 - 3.0	thou/µL
METHOD: CALCULATED PA	RAMETER			
ABSOLUTE MONOCY	YTE COUNT	0.37	0.2 - 1.0	thou/µL
METHOD: CALCULATED PA	RAMETER			
ABSOLUTE EOSINO	PHIL COUNT	0.16	0.02 - 0.50	thou/µL
METHOD: CALCULATED PA	RAMETER			
NEUTROPHIL LYMPH	HOCYTE RATIO (NLR)	1.5		
METHOD: CALCULATED PA	RAMETER			

Interpretation(s)
RBC AND PLATELET INDICES-Mentzer index (MCV/RBC) is an automated cell-counter based calculated screen tool to differentiate cases of Iron deficiency anaemia(>13) from Beta thalassaemia trait

(<13) in patients with microcytic anaemia. This needs to be interpreted in line with clinical correlation and suspicion. Estimation of HbA2 remains the gold standard for diagnosing a case of beta thalassaemia trait.

was in the patients of the patients of the patients of the patients. When age = 49.5 years old and NLR = 3.3, 46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR = 3.4, 46.1% COVID-19 patients with mild disease might become severe.

3.3, COVID-19 patients tend to show mild disease. (Reference to - The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients; A.-P. Yang, et al.; International Immunopharmacology 84 (2020) 106504 This ratio element is a calculated parameter and out of NABL scope.

Ritu Pankay

Dr. Ritu Pankaj, MD, PDCC Senior Consultant, 30897

Dr. Shafira Garg (MD, Pathology) Attending Consultant, 47150

Meenahsh Malhotra

Dr. Meenakshi Malhotra, MD Senior Consultant, 48159





Page 2 Of 20





CLINICAL LABORATORY

Fortis Heart Institute & Multispeciality Hospital, Sector 62, Phase Viii,

Mohali, 160062 Punjab, India

Tel: 0172-469-2222 Extn. 6726, 6727), 0172-469-2221 - CIN -







REF. DOCTOR: SELF PATIENT NAME: AMIT KUMAR

FORTIS MOHALI-CHC -SPLZD FORTIS HOSPITAL # MOHALI,

MOHALI 160062 7087030817

ACCESSION NO : 0006WE011801

PATIENT ID : FH.11716120 CLIENT PATIENT ID: UID:11716120

ABHA NO

AGE/SEX :33 Years :13/05/2023 09:46:00 DRAWN

RECEIVED : 13/05/2023 13:53:25 REPORTED :13/05/2023 16:18:37

CLINICAL INFORMATION:

UID:11716120 REQNO-1521799

CORP-OPD

BILLNO-10021230PCS007376 BILLNO-10021230PCS007376

Test Report Status Results **Biological Reference Interval** Units <u>Final</u>

HAEMATOLOGY

ERYTHROCYTE SEDIMENTATION RATE (ESR), WHOLE BLOOD

0 - 14mm at 1 hr E.S.R

METHOD: WESTERGREN METHOD

Interpretation(s)
ERYTHROCYTE SEDIMENTATION RATE (ESR), WHOLE BLOOD-TEST DESCRIPTION:

Erythrocyte sedimentation rate (ESR) is a test that indirectly measures the degree of inflammation present in the body. The test actually measures the rate of fall (sedimentation) of erythrocytes in a sample of blood that has been placed into a tall, thin, vertical tube. Results are reported as the millimetres of clear fluid (plasma) that are present at the top portion of the tube after one hour. Nowadays' fully automated instruments are available to measure ESR.

ESR is not diagnostic; it is a non-specific test that may be elevated in a number of different conditions. It provides general information about the presence of an inflammatory condition.CRP is superior to ESR because it is more sensitive and reflects a more rapid change.

TEST INTERPRETATION

Increase in: Infections, Vasculities, Inflammatory arthritis, Renal disease, Anemia, Malignancies and plasma cell dyscrasias, Acute allergy Tissue injury, Pregnancy, Estrogen medication, Aging

Finding a very accelerated ESR(>100 mm/hour) in patients with ill-defined symptoms directs the physician to search for a systemic disease (Paraproteinemias,

Disseminated malignancies, connective tissue disease, severe infections such as bacterial endocarditis). In pregnancy BRI in first trimester is 0-48 mm/hr(62 if anemic) and in second trimester (0-70 mm /hr(95 if anemic). ESR returns to normal 4th week post partum.

Decreased in: Polycythermia vera, Sickle cell anemia

False elevated ESR: Increased fibrinogen, Drugs(Vitamin A, Dextran etc), Hypercholesterolemia

False Decreased: Poikilocytosis, (SickleCells, spherocytes), Microcytosis, Low fibrinogen, Very high WBC counts, Drugs (Quinine,

salicylates)

REFERENCE:

1. Nathan and Oski's Haematology of Infancy and Childhood, 5th edition; 2. Paediatric reference intervals. AACC Press, 7th edition. Edited by S. Soldin; 3. The reference for the adult reference range is "Practical Haematology by Dacie and Lewis, 10th edition.

Ritu Pantay

Dr. Ritu Pankaj, MD, PDCC Senior Consultant, 30897

Dr. Shafira Garg (MD, Pathology) Attending Consultant, 47150

Meenahshi Malhotra

Dr. Meenakshi Malhotra, MD Senior Consultant, 48159





Page 3 Of 20

View Report



CLINICAL LABORATORY

Fortis Heart Institute & Multispeciality Hospital, Sector 62, Phase Viii,

Mohali, 160062 Punjab, India

Tel: 0172-469-2222 Extn. 6726, 6727), 0172-469-2221 - CIN -







FORTIS MOHALI-CHC -SPLZD FORTIS HOSPITAL # MOHALI,

MOHALI 160062 7087030817 ACCESSION NO : **0006WE011801**PATIENT ID : FH.11716120

CLIENT PATIENT ID: UID:11716120

ABHA NO :

AGE/SEX :33 Years Male
DRAWN :13/05/2023 09:46:00
RECEIVED :13/05/2023 13:53:25
REPORTED :13/05/2023 16:18:37

CLINICAL INFORMATION:

UID:11716120 REQNO-1521799

CORP-OPD

BILLNO-10021230PCS007376 BILLNO-10021230PCS007376

Test Report Status	Final	Results	Biological Reference Interval Units

	BIOCHEMISTRY		
LIVER FUNCTION PROFILE, SERUM			
BILIRUBIN, TOTAL METHOD: DIAZONIUM ION, BLANKED (ROCHE)	0.90	UPTO 1.2	mg/dL
BILIRUBIN, DIRECT METHOD: DIAZOTIZATION	0.25	0.00 - 0.30	mg/dL
BILIRUBIN, INDIRECT METHOD: CALCULATED PARAMETER	0.65 High	0.00 - 0.60	mg/dL
TOTAL PROTEIN METHOD: BIURET	7.5	6.6 - 8.7	g/dL
ALBUMIN METHOD: BROMOCRESOL GREEN	4.9	3.97 - 4.94	g/dL
GLOBULIN	2.6	2.0 - 4.0 Neonates - Pre Mature: 0.29 - 1.04	g/dL
METHOD: CALCULATED PARAMETER ALBUMIN/GLOBULIN RATIO METHOD: CALCULATED PARAMETER	1.9	1.0 - 2.0	RATIO
ASPARTATE AMINOTRANSFERASE(AST/SGOT)	54 High	0 - 40	U/L
ALANINE AMINOTRANSFERASE (ALT/SGPT) METHOD: UV WITHOUT PYRIDOXAL-5 PHOSPHATE	118 High	0 - 41	U/L
ALKALINE PHOSPHATASE METHOD: PNPP - AMP BUFFER	136 High	40 - 129	U/L
GAMMA GLUTAMYL TRANSFERASE (GGT) METHOD: GAMMA GLUTAMYLCARBOXY 4NITROANILIDE	163 High	8 - 61	U/L
LACTATE DEHYDROGENASE METHOD: LACTATE -PYRUVATE UV	208	135 - 225	U/L

GLUCOSE FASTING, FLUORIDE PLASMA

FBS (FASTING BLOOD SUGAR) 82 74 - 106 mg/dL

METHOD: HEXOKINASE

Ritu Pankay

Dr. Ritu Pankaj, MD, PDCC Senior Consultant,30897

Dr. Meenakshi Malhotra, MD Senior Consultant,48159

Meenahahi Malhotra

Ms. Hardeep Kaur, M.Sc. Biochemistry Page 4 Of 20





View Details

View Report



CLINICAL LABORATORY Fortis Heart Institute & Multispeciality Hospital, Sector 62, Phase Viii,

Mohali, 160062 Punjab, India

Tel: 0172-469-2222 Extn. 6726, 6727), 0172-469-2221 - CIN -







FORTIS MOHALI-CHC -SPLZD FORTIS HOSPITAL # MOHALI,

MOHALI 160062 7087030817

ACCESSION NO : 0006WE011801 PATIENT ID : FH.11716120 CLIENT PATIENT ID: UID:11716120

ABHA NO

AGE/SEX :33 Years DRAWN :13/05/2023 09:46:00 RECEIVED : 13/05/2023 13:53:25

REPORTED :13/05/2023 16:18:37


CLINICAL INFORMATION:

UID:11716120 REQNO-1521799

CORP-OPD

BILLNO-10021230PCS007376 BILLNO-10021230PCS007376

Test Report Status Results **Biological Reference Interval** Units <u>Final</u>



BLOOD UREA NITROGEN (BUN), SERUM

6 - 20 mg/dL **BLOOD UREA NITROGEN** 17

METHOD: UREASE - UV

Ritu Pantay

Dr. Ritu Pankaj, MD, PDCC Senior Consultant, 30897

Meenahahi Malhotra

Dr. Meenakshi Malhotra, MD Senior Consultant, 48159

Ms. Hardeep Kaur, M.Sc. **Biochemistry**







CLINICAL LABORATORY Fortis Heart Institute & Multispeciality Hospital, Sector 62, Phase Viii, Mohali, 160062

Punjab, India

Tel: 0172-469-2222 Extn. 6726, 6727), 0172-469-2221 - CIN -

Email: srl.mohali@fortishealthcare.com



L85110DL1996PLC076704

Page 5 Of 20





FORTIS MOHALI-CHC -SPLZD FORTIS HOSPITAL # MOHALI,

MOHALI 160062 7087030817

ACCESSION NO : 0006WE011801 PATIENT ID : FH.11716120 CLIENT PATIENT ID: UID:11716120

ABHA NO

AGE/SEX :33 Years :13/05/2023 09:46:00 RECEIVED : 13/05/2023 13:53:25 REPORTED :13/05/2023 16:18:37


CLINICAL INFORMATION:

UID:11716120 REQNO-1521799

CORP-OPD

BILLNO-10021230PCS007376 BILLNO-10021230PCS007376

Test Report Status Results **Biological Reference Interval Units** <u>Final</u>



URIC ACID, SERUM

URIC ACID 5.5 3.4 - 7.0mg/dL

METHOD: URICASE, COLORIMETRIC

GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE BLOOD

Non-diabetic: < 5.7 HBA1C 4.8 %

> Pre-diabetics: 5.7 - 6.4 Diabetics: > or = 6.5Therapeutic goals: < 7.0 Action suggested : > 8.0 (ADA Guideline 2021)

METHOD: HPLC

ESTIMATED AVERAGE GLUCOSE(EAG) 91.1 < 116.0 mg/dL

METHOD: CALCULATED PARAMETER

Dr. Ritu Pankaj, MD, PDCC Dr. Meenakshi Malhotra, MD Senior Consultant, 30897 Senior Consultant, 48159

Meenahsh Malhotre

Ms. Hardeep Kaur, M.Sc. **Biochemistry**



Page 6 Of 20





CLINICAL LABORATORY

Fortis Heart Institute & Multispeciality Hospital, Sector 62, Phase Viii,

Mohali, 160062 Punjab, India

Ritu Pankay

Tel: 0172-469-2222 Extn. 6726, 6727), 0172-469-2221 - CIN -







FORTIS MOHALI-CHC -SPLZD FORTIS HOSPITAL # MOHALI,

MOHALI 160062 7087030817

ACCESSION NO : 0006WE011801 PATIENT ID : FH.11716120

CLIENT PATIENT ID: UID:11716120

ABHA NO

AGE/SEX :33 Years :13/05/2023 09:46:00 RECEIVED : 13/05/2023 13:53:25

REPORTED :13/05/2023 16:18:37


CLINICAL INFORMATION:

UID:11716120 REQNO-1521799

CORP-OPD

BILLNO-10021230PCS007376 BILLNO-10021230PCS007376

Test Report Status Results **Biological Reference Interval** Units <u>Final</u>



CREATININE EGFR

0.70 - 1.20CREATININE 1.00 mg/dL METHOD: ALKALINE PICRATE-KINETIC

AGE 33 years

Ritu Pantay

Meenahah Malhotra Dr. Ritu Pankaj, MD, PDCC

Dr. Meenakshi Malhotra, MD Senior Consultant, 48159

Ms. Hardeep Kaur, M.Sc. **Biochemistry**

Page 7 Of 20







Senior Consultant, 30897

CLINICAL LABORATORY Fortis Heart Institute & Multispeciality Hospital, Sector 62, Phase Viii,

Mohali, 160062 Punjab, India

Tel: 0172-469-2222 Extn. 6726, 6727), 0172-469-2221 - CIN -







FORTIS MOHALI-CHC -SPLZD FORTIS HOSPITAL # MOHALI,

MOHALI 160062 7087030817

ACCESSION NO : 0006WE011801 PATIENT ID : FH.11716120 CLIENT PATIENT ID: UID:11716120

ABHA NO

AGE/SEX :33 Years :13/05/2023 09:46:00 RECEIVED : 13/05/2023 13:53:25 REPORTED :13/05/2023 16:18:37

CLINICAL INFORMATION:

UID:11716120 REQNO-1521799

CORP-OPD


BILLNO-10021230PCS007376 BILLNO-10021230PCS007376

Test Report Status	Final	Results	Biological Reference Interval Units

GLOMERULAR FILTRATION RATE (MALE)

86

GFR of +90 normal or minimal kidney damage with normal GFR 89-60 mild decrease 59-30 moderate decrease 29-15 severe decrease < 15 kidney failure (units: mL/min/1.73mSq.)



GLUCOSE POST-PRANDIAL, PLASMA

PPBS(POST PRANDIAL BLOOD SUGAR)

162 High

Non-Diabetes 70 - 140

mg/dL

METHOD: HEXOKINASE

Dr. Ritu Pankaj, MD, PDCC

Senior Consultant, 30897

Ritu Pantay

Meenahsh Malhotra

Dr. Meenakshi Malhotra, MD Senior Consultant, 48159

Ms. Hardeep Kaur, M.Sc. **Biochemistry**



Page 8 Of 20



CLINICAL LABORATORY Fortis Heart Institute & Multispeciality Hospital, Sector 62, Phase Viii, Mohali, 160062

Punjab, India

Tel: 0172-469-2222 Extn. 6726, 6727), 0172-469-2221 - CIN -







FORTIS MOHALI-CHC -SPLZD FORTIS HOSPITAL # MOHALI,

MOHALI 160062 7087030817 ACCESSION NO : **0006WE011801**PATIENT ID : FH.11716120

CLIENT PATIENT ID: UID:11716120

ABHA NO :

AGE/SEX :33 Years Male
DRAWN :13/05/2023 09:46:00
RECEIVED :13/05/2023 13:53:25

REPORTED :13/05/2023 16:18:37


CLINICAL INFORMATION:

UID:11716120 REQNO-1521799

CORP-OPD

BILLNO-10021230PCS007376 BILLNO-10021230PCS007376

Test Report Status <u>Final</u> Results Biological Reference Interval Units



Interpretation(s)

LIVER FUNCTION PROFILE, SERUM-

Bilirubin is a yellowish pigment found in bile and is a breakdown product of normal heme catabolism. Bilirubin is excreted in bile and urine, and elevated levels may give yellow discoloration in jaundice. Elevated levels results from increased bilirubin production (eg, hemolysis and ineffective erythropoiesis), decreased bilirubin excretion (eg, obstruction and hepatitis), and abnormal bilirubin metabolism (eg, hereditary and neonatal jaundice). Conjugated (direct) bilirubin is elevated more than unconjugated (indirect) bilirubin in Viral hepatitis, Drug reactions, Alcoholic liver disease Conjugated (direct) bilirubin is also elevated more than unconjugated (indirect) bilirubin metabolism (eg, hereditary and neonatal jaundice). Conjugated (direct) bilirubin in Viral hepatitis, Drug reactions, Alcoholic liver disease Conjugated (direct) bilirubin is also elevated more than unconjugated (indirect) bilirubin metabolism (indirect) bilirubin indirect) b

AST is an enzyme found in various parts of the body. AST is found in the liver, heart, skeletal muscle, kidneys, brain, and red blood cells, and it is commonly measured clinically as a marker for liver health. AST levels increase during chronic viral hepatitis, blockage of the bile duct, cirrhosis of the liver, liver cancer, kidney failure, hemolytic anemia, pancreatitis, hemochromatosis. AST levels may also increase after a heart attack or strenuous activity. ALT test measures the amount of this enzyme in the blood. ALT is found mainly in the liver, but also in smaller amounts in the kidneys, heart, muscles, and pancreas. It is commonly measured as a part of a diagnostic evaluation of hepatocellular injury, to determine liver health. AST levels increase during acute hepatitis, sometimes due to a viral infection, ischemia to the liver, chronic hepatitis, obstruction of bile ducts, cirrhosis.

ALP is a protein found in almost all body tissues. Tissues with higher amounts of ALP include the liver, bile ducts and bone. Elevated ALP levels are seen in Biliary obstruction, Osteoblastic bone tumors, osteomalacia, hepatitis, Hyperparathyroidism, Leukemia, Lymphoma, Pagets disease, Rickets, Sarcoidosis etc. Lower-than-normal ALP levels seen in Hypophosphatasia. Malnutrition. Protein deficiency. Wilsons disease.

GGT is an enzyme found in cell membranes of many tissues mainly in the liver, kidney and pancreas. It is also found in other tissues including intestine, spleen, heart, brain and seminal vesicles. The highest concentration is in the kidney, but the liver is considered the source of normal enzyme activity. Serum GGT has been widely used as an

Ritu Pantoy

Meenahshi Malhotra

Dr. Meenakshi Malhotra, MD Senior Consultant,48159 Ms. Hardeep Kaur, M.Sc. Biochemistry Page 9 Of 20





View Details

View Report



CLINICAL LABORATORY

Dr. Ritu Pankaj, MD, PDCC

Senior Consultant, 30897

Fortis Heart Institute & Multispeciality Hospital, Sector 62, Phase Viii,

Mohali, 160062 Punjab, India

Tel: 0172-469-2222 Extn. 6726, 6727), 0172-469-2221 - CIN -







REF. DOCTOR: SELF PATIENT NAME: AMIT KUMAR

FORTIS MOHALI-CHC -SPLZD FORTIS HOSPITAL # MOHALI,

MOHALT 160062 7087030817

ACCESSION NO : 0006WE011801 PATIENT ID : FH.11716120 CLIENT PATIENT ID: UID:11716120

ABHA NO

AGE/SEX :33 Years :13/05/2023 09:46:00 DRAWN RECEIVED: 13/05/2023 13:53:25

REPORTED :13/05/2023 16:18:37

CLINICAL INFORMATION:

UID:11716120 REQNO-1521799

CORP-OPD

BILLNO-10021230PCS007376 BILLNO-10021230PCS007376

Test Report Status Results **Biological Reference Interval** Units <u>Final</u>

index of liver dysfunction. Elevated serum GGT activity can be found in diseases of the liver, biliary system and pancreas. Conditions that increase serum GGT are obstructive liver disease, high alcohol consumption and use of enzyme-inducing drugs etc.

Total Protein also known as total protein, is a biochemical test for measuring the total amount of protein in serum. Protein in the plasma is made up of albumin and globulin. Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstroms disease. Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage), Burns, Glomerulonephritis, Liver disease, Malabsorption, Malnutrition, Nephrotic syndrome, Protein-losing enteropathy etc.

Albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. Low blood albumin levels (hypoalbuminemia) can be caused by:Liver disease like cirrhosis of the liver, nephrotic syndrome,protein-losing enteropathy,Burns,hemodilution,increased vascular permeability or decreased lymphatic clearance,malnutrition and wasting etc GLUCOSE FASTING,FLUORIDE PLASMA-**TEST DESCRIPTION**

Normally, the glucose concentration in extracellular fluid is closely regulated so that a source of energy is readily available to tissues and sothat no glucose is excreted in the

Increased in:Diabetes mellitus, Cushing's syndrome (10 – 15%), chronic pancreatitis (30%). Drugs:corticosteroids,phenytoin, estrogen, thiazides.

Decreased in:Pancreatic islet cell disease with increased insulin,insulinoma,adrenocortical insufficiency,hypopituitarism,diffuse liver disease, malignancy(adrenocortical,stomach,fibrosarcoma),infant of a diabetic mother,enzyme deficiency

diseases(e.g.galactosemia), Drugs-insulin, ethanol, propranolol; sulfonylureas, tolbutamide, and other oral hypoglycemic agents.

NOTE: While random serum glucose levels correlate with home glucose monitoring results (weekly mean capillary glucose values), there is wide fluctuation within individuals.Thus, glycosylated hemoglobin(HbA1c) levels are favored to monitor glycemic control.

High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glyosuria, Glycaemic

index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc.

BLOOD UREA NITROGEN (BUN), SERUM-Causes of Increased levels include Pre renal (High protein diet, Increased protein catabolism, GI haemorrhage, Cortisol, Dehydration, CHF Renal), Renal Failure, Post Renal (Malignancy, Nephrolithiasis, Prostatism)

Causes of decreased level include Liver disease, SIADH.

URIC ACID, SERUM-Causes of Increased levels:-Dietary(High Protein Intake,Prolonged Fasting,Rapid weight loss),Gout,Lesch nyhan syndrome,Type 2 DM,Metabolic syndrome Causes of decreased levels-Low Zinc intake, OCP, Multiple Sclerosis GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE BLOOD-Used For:

- 1. Evaluating the long-term control of blood glucose concentrations in diabetic patients.
- 2. Diagnosing diabetes.
- 3. Identifying patients at increased risk for diabetes (prediabetes).

The ADA recommends measurement of HbA1c (typically 3-4 times per year for type 1 and poorly controlled type 2 diabetic patients, and 2 times per year for well-controlled type 2 diabetic patients) to determine whether a patients metabolic control has remained continuously within the target range.

- 1. eAG (Estimated average glucose) converts percentage HbA1c to md/dl, to compare blood glucose levels
- eAG gives an evaluation of blood glucose levels for the last couple of months.
- 3. eAG is calculated as eAG (mg/dl) = 28.7 * HbA1c 46.7

HbA1c Estimation can get affected due to :

- 1. Shortened Erythrocyte survival: Any condition that shortens erythrocyte survival or decreases mean erythrocyte age (e.g. recovery from acute blood loss,hemolytic anemia) will falsely lower HbA1c test results.Fructosamine is recommended in these patients which indicates diabetes control over 15 days.
- 2. Vitamin C & E are reported to falsely lower test results. (possibly by inhibiting glycation of hemoglobin. 3. Iron deficiency anemia is reported to increase test results. Hypertriglyceridemia, uremia, hyperbilirubinemia, chronic alcoholism, chronic ingestion of salicylates & opiates addiction are reported to interfere with some assay methods, falsely increasing results.
- 4. Interference of hemoglobinopathies in HbA1c estimation is seen in

- a) Homozygous hemoglobinopathy. Fructosamine is recommended for testing of HbA1c.
 b) Heterozygous state detected (D10 is corrected for HbS & HbC trait.)
 c) HbF > 25% on alternate paltform (Boronate affinity chromatography) is recommended for testing of HbA1c.Abnormal Hemoglobin electrophoresis (HPLC method) is recommended for detecting a hemoglobinopathy
 CREATININE EGFR-GFR— Glomerular filtration rate (GFR) is a measure of the function of the kidneys. The GFR is a calculation based on a serum creatinine test. Creatinine

is a muscle waste product that is filtered from the blood by the kidneys and excreted into urine at a relatively steady rate. When kidney function decreases, less creatinine is excreted and concentrations increase in the blood. With the creatinine test, a reasonable estimate of the actual GFR can be determined. A GFR of 60 or higher is in the normal range.

A GFR below 60 may mean kidney disease

A GFR of 15 or lower may mean kidney failure.

Estimated GFR (eGFR) is the preferred method for identifying people with chronic kidney disease (CKD). In adults, eGFR calculated using the Modification of Diet in Renal

Ritu Pantoy

Meenahshi Malhotra

Dr. Meenakshi Malhotra, MD Senior Consultant, 48159

Ms. Hardeep Kaur, M.Sc. **Biochemistry**

Page 10 Of 20

View Report



CLINICAL LABORATORY

Dr. Ritu Pankaj, MD, PDCC

Senior Consultant, 30897

Fortis Heart Institute & Multispeciality Hospital, Sector 62, Phase Viii,

Mohali, 160062 Punjab, India

L85110DL1996PLC076704 Email: srl.mohali@fortishealthcare.com

Tel: 0172-469-2222 Extn. 6726, 6727), 0172-469-2221 - CIN -







FORTIS MOHALI-CHC -SPLZD FORTIS HOSPITAL # MOHALI,

MOHALI 160062 7087030817 ACCESSION NO : **0006WE011801**

PATIENT ID : FH.11716120 CLIENT PATIENT ID: UID:11716120

ABHA NO

AGE/SEX :33 Years Male DRAWN :13/05/2023 09:46:00

RECEIVED : 13/05/2023 13:53:25 REPORTED :13/05/2023 16:18:37

CLINICAL INFORMATION:

UID:11716120 REQNO-1521799

CORP-OPD

BILLNO-10021230PCS007376 BILLNO-10021230PCS007376

Test Report Status <u>Final</u> Results Biological Reference Interval Units

Disease (MDRD) Study equation provides a more clinically useful measure of kidney function than serum creatinine alone.

This equation takes into account several factors that impact creatinine production, including age, gender, and race. In children, eGFR is calculated using original schwartz equation.

The equation has not been validated in children & will only be reported for patients > 16 years of age. The equation is normalized for an average adult body surface area of 1.73m², weight & height adjustment is not necessary.

The IDMS Traceable MDRD equation has not been validated in children & will only be reported for patients = 18 years of age. The equation is normalized for an average adult body surface area of 1.73m², weight & height adjustment is not necessary. Estimation of GFR in children and adolescence (0- < 18 years) is performed by bedside IDMS- Traceable Schwartz formula

GLUCOSE POST-PRANDIAL, PLASMA-Spectrophotometry Hexokinase

Ritu Pankaj

Dr. Ritu Pankaj, MD, PDCC Senior Consultant,30897 Meenahsh: Malhotra

Dr. Meenakshi Malhotra, MD Senior Consultant,48159 Ms. Hardeep Kau

Ms. Hardeep Kaur, M.Sc. Biochemistry



Page 11 Of 20

View Details

View Report



CLINICAL LABORATORY
Fortis Heart Institute & Multispeciality Hospital, Sector 62, Phase Viii, Mohali, 160062

Punjab, India

Tel: 0172-469-2222 Extn. 6726, 6727), 0172-469-2221 - CIN -







FORTIS MOHALI-CHC -SPLZD FORTIS HOSPITAL # MOHALI,

MOHALI 160062 7087030817

ACCESSION NO : 0006WE011801 PATIENT ID : FH.11716120 CLIENT PATIENT ID: UID:11716120

ABHA NO

AGE/SEX :33 Years Male :13/05/2023 09:46:00 RECEIVED: 13/05/2023 13:53:25 REPORTED :13/05/2023 16:18:37

CLINICAL INFORMATION:

UID:11716120 REQNO-1521799

CORP-OPD

BILLNO-10021230PCS007376 BILLNO-10021230PCS007376

Test Report Status Results **Biological Reference Interval** <u>Final</u>

BIOCHEMISTRY - LIPID

ITDID	DDAETI	.E. SERUM
LIPID	PRUFIL	.c. sekum

CHOLESTEROL, TOTAL 244 High < 200 Desirable mg/dL

200 - 239 Borderline High

>/= 240 High

METHOD: CHOLESTEROL OXIDASE, ESTERASE, PEROXIDASE

mg/dL 217 High < 150 Normal TRIGLYCERIDES

150 - 199 Borderline High

200 - 499 High >/= 500 Very High

METHOD: ENZYMATIC ASSAY

HDL CHOLESTEROL 47 < 40 Low mg/dL

>/=60 High

METHOD: DIRECT MEASURE - PEG

154 High mg/dL LDL CHOLESTEROL, DIRECT < 100 Optimal

100 - 129 Near or above

optimal

130 - 160 Borderline High

161 - 189 High >/= 190 Very High

METHOD: CHOLESTEROL OXIDASE, ESTERASE, PEROXIDASE

197 High NON HDL CHOLESTEROL Desirable: Less than 130

mg/dL Above Desirable: 130 - 159 Borderline High: 160 - 189

High: 190 - 219 Very high: > or = 220

VERY LOW DENSITY LIPOPROTEIN 43.4 High mg/dL Desirable value :

10 - 35

METHOD: CALCULATED PARAMETER

CHOL/HDL RATIO 5.2 High 3.3-4.4 Low Risk

4.5-7.0 Average Risk 7.1-11.0 Moderate Risk

> 11.0 High Risk

Dr. Ritu Pankaj, MD, PDCC Senior Consultant, 30897

Ms. Hardeep Kaur, M.Sc. **Biochemistry**

Meenahsh Malhot

Dr. Meenakshi Malhotra, MD Senior Consultant, 48159





Page 12 Of 20





Fortis Heart Institute & Multispeciality Hospital, Sector 62, Phase Viii, Mohali, 160062

Punjab, India

Tel: 0172-469-2222 Extn. 6726, 6727), 0172-469-2221 - CIN -

L85110DL1996PLC076704

Email: srl.mohali@fortishealthcare.com







FORTIS MOHALI-CHC -SPLZD FORTIS HOSPITAL # MOHALI,

MOHALI 160062 7087030817

ACCESSION NO : 0006WE011801 PATIENT ID : FH.11716120 CLIENT PATIENT ID: UID:11716120

ABHA NO

AGE/SEX :33 Years :13/05/2023 09:46:00 RECEIVED: 13/05/2023 13:53:25 REPORTED :13/05/2023 16:18:37

CLINICAL INFORMATION:

UID:11716120 REQNO-1521799 CORP-OPD

BILLNO-10021230PCS007376 BILLNO-10021230PCS007376


Test Report Status Results Biological Reference Interval Units <u>Final</u>

3.3 High LDL/HDL RATIO 0.5 - 3.0 Desirable/Low Risk 3.1 - 6.0 Borderline/Moderate

Risk

>6.0 High Risk

METHOD: CALCULATED PARAMETER



Ritu Pantay

Dr. Ritu Pankaj, MD, PDCC Senior Consultant, 30897

Ms. Hardeep Kaur, M.Sc. **Biochemistry**

Meenahsh Malhotra

Dr. Meenakshi Malhotra, MD Senior Consultant, 48159





Page 13 Of 20



CLINICAL LABORATORY Fortis Heart Institute & Multispeciality Hospital, Sector 62, Phase Viii, Mohali, 160062

Punjab, India

Tel: 0172-469-2222 Extn. 6726, 6727), 0172-469-2221 - CIN -

L85110DL1996PLC076704

Email: srl.mohali@fortishealthcare.com







FORTIS MOHALI-CHC -SPLZD FORTIS HOSPITAL # MOHALI,

MOHALI 160062 7087030817 ACCESSION NO: **0006WE011801**PATIENT ID: FH.11716120
CLIENT PATIENT ID: UID:11716120

ABHA NO :

AGE/SEX :33 Years Male
DRAWN :13/05/2023 09:46:00
RECEIVED :13/05/2023 13:53:25
REPORTED :13/05/2023 16:18:37


CLINICAL INFORMATION:

UID:11716120 REQNO-1521799

CORP-OPD

BILLNO-10021230PCS007376 BILLNO-10021230PCS007376

Test Report Status <u>Final</u> Results Biological Reference Interval Units



Ritu Pantay

Dr. Ritu Pankaj, MD, PDCC Senior Consultant,30897 Kong

Ms. Hardeep Kaur, M.Sc. Biochemistry Meenahshi Malhotra

Dr. Meenakshi Malhotra, MD Senior Consultant,48159





Page 14 Of 20

View Details

View Report



CLINICAL LABORATORY
Fortis Heart Institute & Multispeciality Hospital, Sector 62,Phase Viii, Mohali, 160062

Punjab, India

Tel: 0172-469-2222 Extn. 6726, 6727), 0172-469-2221 - CIN - L85110DL1996PLC076704

Email: srl.mohali@fortishealthcare.com







FORTIS MOHALI-CHC -SPLZD FORTIS HOSPITAL # MOHALI,

MOHALI 160062 7087030817

ACCESSION NO : 0006WE011801 : FH.11716120

CLIENT PATIENT ID: UID:11716120

ABHA NO

PATIENT ID

AGE/SEX :33 Years DRAWN :13/05/2023 09:46:00 RECEIVED: 13/05/2023 13:53:25 REPORTED :13/05/2023 16:18:37


CLINICAL INFORMATION:

UID:11716120 REQNO-1521799

CORP-OPD

BILLNO-10021230PCS007376 BILLNO-10021230PCS007376

Test Report Status Results **Biological Reference Interval** Units <u>Final</u>



Ritu Pantay

Dr. Ritu Pankaj, MD, PDCC Senior Consultant, 30897

Ms. Hardeep Kaur, M.Sc. **Biochemistry**

Meenahshi Malhotra

Dr. Meenakshi Malhotra, MD Senior Consultant, 48159





Page 15 Of 20

View Report



Fortis Heart Institute & Multispeciality Hospital, Sector 62, Phase Viii,

Tel: 0172-469-2222 Extn. 6726, 6727), 0172-469-2221 - CIN -

L85110DL1996PLC076704 Email: srl.mohali@fortishealthcare.com



CLINICAL LABORATORY

Mohali, 160062 Punjab, India





FORTIS MOHALI-CHC -SPLZD FORTIS HOSPITAL # MOHALI,

MOHALI 160062 7087030817

ACCESSION NO : 0006WE011801

PATIENT ID : FH.11716120 CLIENT PATIENT ID: UID:11716120

ABHA NO

AGE/SEX :33 Years :13/05/2023 09:46:00 RECEIVED: 13/05/2023 13:53:25

REPORTED :13/05/2023 16:18:37


CLINICAL INFORMATION:

UID:11716120 REQNO-1521799

CORP-OPD

BILLNO-10021230PCS007376 BILLNO-10021230PCS007376

Test Report Status Results **Biological Reference Interval** Units <u>Final</u>



Interpretation(s)

Dr. Ritu Pankaj, MD, PDCC

Senior Consultant, 30897

Ritu Pantay

Ms. Hardeep Kaur, M.Sc. **Biochemistry**

Dr. Meenakshi Malhotra, MD Senior Consultant, 48159

Meenahshi Malhotra



Page 16 Of 20

View Report



CLINICAL LABORATORY Fortis Heart Institute & Multispeciality Hospital, Sector 62, Phase Viii, Mohali, 160062

Punjab, India

Tel: 0172-469-2222 Extn. 6726, 6727), 0172-469-2221 - CIN -

L85110DL1996PLC076704

Email: srl.mohali@fortishealthcare.com







FORTIS MOHALI-CHC -SPLZD FORTIS HOSPITAL # MOHALI,

MOHALI 160062 7087030817

ACCESSION NO : 0006WE011801 PATIENT ID : FH.11716120 CLIENT PATIENT ID: UID:11716120

ABHA NO

AGE/SEX :33 Years :13/05/2023 09:46:00 RECEIVED: 13/05/2023 13:53:25 REPORTED: 13/05/2023 16:18:37

CLINICAL INFORMATION:

UID:11716120 REQNO-1521799

CORP-OPD

BILLNO-10021230PCS007376 BILLNO-10021230PCS007376

Results **Test Report Status Biological Reference Interval** Units <u>Final</u>

CLINICAL PATH - URINALYSIS

URINALYSIS

PHYSICAL EXAMINATION, URINE

COLOR YELLOW

METHOD: MANUAL EXAMINATION

APPEARANCE CLEAR

METHOD: MANUAL EXAMINATION

CHEMICAL EXAMINATION, URINE

4.7 - 7.55.5 PH

METHOD: DOUBLE INDICATOR PRINCIPLE

SPECIFIC GRAVITY >=1.030 1.003 - 1.035

METHOD: REFLECTANCE PHOTOMETRY (IONIC CONCENTRATION)

DETECTED (TRACE) NOT DETECTED

METHOD: REFLECTION PHOTOMETRY (PROTEIN ERROR INDICATOR)

GLUCOSE NOT DETECTED NOT DETECTED

METHOD: REFLECTANCE PHOTOMETRY (GLUCOSE OXIDASE METHOD)

NOT DETECTED **KFTONES** NOT DETECTED

METHOD: REFLECTION PHOTOMETRY (NITROPRUSSIDE)

BLOOD NOT DETECTED NOT DETECTED

METHOD: REFLECTANCE PHOTOMETRY (BENZIDINE REACTION)

NOT DETECTED NOT DETECTED BILIRUBIN

METHOD: REFLECTANCE SPECTROPHOTOMETRY (DIAZO REACTION)

UROBILINOGEN NORMAL **NORMAL**

METHOD: REFLECTANCE PHOTOMETRY (EHRLICH'S REACTION)

NOT DETECTED NOT DETECTED **NITRITE**

METHOD: REFLECTANCE SPECTROPHOTOMETRY (DIAZO REACTION)

MICROSCOPIC EXAMINATION, URINE

Meenahah Malhot

Ritu Panta

Page 17 Of 20

Dr. Irneet Mundi, MD Associate Consultant, 34080 Dr. Meenakshi Malhotra, MD Senior Consultant, 48159

Dr. Ritu Pankaj, MD, PDCC Senior Consultant, 30897





CLINICAL LABORATORY Fortis Heart Institute & Multispeciality Hospital, Sector 62, Phase Viii, Mohali, 160062

Punjab, India

Tel: 0172-469-2222 Extn. 6726, 6727), 0172-469-2221 - CIN -

L85110DL1996PLC076704

Email: srl.mohali@fortishealthcare.com







FORTIS MOHALI-CHC -SPLZD FORTIS HOSPITAL # MOHALI,

MOHALI 160062 7087030817

ACCESSION NO : 0006WE011801 PATIENT ID : FH.11716120 CLIENT PATIENT ID: UID:11716120

ABHA NO

AGE/SEX :33 Years :13/05/2023 09:46:00 RECEIVED: 13/05/2023 13:53:25 REPORTED :13/05/2023 16:18:37

CLINICAL INFORMATION:

UID:11716120 REQNO-1521799

CORP-OPD

BILLNO-10021230PCS007376 BILLNO-10021230PCS007376

DILLINO-10021230FC3007370				
Test Report Status <u>Final</u>	Results	Biological Reference I	Biological Reference Interval Units	
RED BLOOD CELLS METHOD: MICROSCOPY	NOT DETECTED	NOT DETECTED	/HPF	
PUS CELL (WBC'S) METHOD: REFLECTANCE PHOTOMETRY & MICROSCOPY	NOT DETECTED	0-5	/HPF	
EPITHELIAL CELLS METHOD: MICROSCOPY	NOT DETECTED	0-5	/HPF	
CASTS METHOD: MICROSCOPY	NOT DETECTED			
CRYSTALS METHOD: MICROSCOPY	NOT DETECTED			
BACTERIA METHOD: MICROSCOPY	NOT DETECTED	NOT DETECTED		
YEAST	NOT DETECTED	NOT DETECTED		

Interpretation(s)

Dr. Irneet Mundi, MD Associate Consultant, 34080 Meenahahi Malhotra

Dr. Meenakshi Malhotra, MD Senior Consultant, 48159

Ritu Pantay

Dr. Ritu Pankaj, MD, PDCC Senior Consultant, 30897





Page 18 Of 20

View Report



CLINICAL LABORATORY Fortis Heart Institute & Multispeciality Hospital, Sector 62, Phase Viii, Mohali, 160062

Punjab, India

L85110DL1996PLC076704 Email: srl.mohali@fortishealthcare.com



Tel: 0172-469-2222 Extn. 6726, 6727), 0172-469-2221 - CIN -





FORTIS MOHALI-CHC -SPLZD FORTIS HOSPITAL # MOHALI,

MOHALI 160062 7087030817 ACCESSION NO: **0006WE011801**PATIENT ID: FH.11716120
CLIENT PATIENT ID: UID:11716120

ABHA NO

AGE/SEX :33 Years Male
DRAWN :13/05/2023 09:46:00
RECEIVED :13/05/2023 13:53:25
REPORTED :13/05/2023 16:18:37

CLINICAL INFORMATION:

UID:11716120 REQNO-1521799

CORP-OPD

BILLNO-10021230PCS007376 BILLNO-10021230PCS007376

Test Report Status Final Results Biological Reference Interval Units

CLINICAL PATH - STOOL ANALYSIS

STOOL: OVA & PARASITE

PHYSICAL EXAMINATION, STOOL

COLOUR YELLOW

CONSISTENCY WELL FORMED

MUCUS NOT DETECTED NOT DETECTED

METHOD: MICROSCOPIC EXAMINATION

VISIBLE BLOOD ABSENT ABSENT ABSENT

ADULT PARASITE NOT DETECTED

METHOD: MANUAL

MICROSCOPIC EXAMINATION, STOOL

PUS CELLS NOT DETECTED /hpf
RED BLOOD CELLS NOT DETECTED NOT DETECTED /HPF

NOT DETECTED

METHOD: MICROSCOPIC EXAMINATION

CYSTS NOT DETECTED NOT DETECTED

METHOD: MICROSCOPIC EXAMINATION

OVA

METHOD: MICROSCOPIC EXAMINATION

LARVAE NOT DETECTED NOT DETECTED

TROPHOZOITES NOT DETECTED NOT DETECTED

METHOD: MICROSCOPIC EXAMINATION

METHOD: MICROSCOPIC EXAMINATION

Interpretation(s)

Dr. Anita Sharma

Dr. Anita Sharma, MD Associate Director ,27672





Page 19 Of 20

View Details

View Report



Fortis Heart Institute & Multispeciality Hospital, Sector 62, Phase Viii, Mohali, 160062

Punjab, India

Tel: 0172-469-2222 Extn. 6726, 6727), 0172-469-2221 - CIN -







FORTIS MOHALI-CHC -SPLZD FORTIS HOSPITAL # MOHALI,

MOHALI 160062 7087030817 ACCESSION NO: **0006WE011801**PATIENT ID: FH.11716120
CLIENT PATIENT ID: UID:11716120

ABHA NO :

AGE/SEX :33 Years Male
DRAWN :13/05/2023 09:46:00
RECEIVED :13/05/2023 13:53:25
REPORTED :13/05/2023 16:18:37

CLINICAL INFORMATION:

UID:11716120 REQNO-1521799

CORP-OPD

BILLNO-10021230PCS007376 BILLNO-10021230PCS007376

Test Report Status	<u>Final</u>	Results	Biological Reference Interval	Units	
--------------------	--------------	---------	--------------------------------------	-------	--

SPECIALISED CHEMISTRY - HORMONE				
THYROID PANEL, SERUM				
T3 METHOD: SANDWICH (ECLIA)	119.4	80.00 - 200.00	ng/dL	
T4 METHOD: SANDWICH (ECLIA)	8.48	5.10 - 14.10	μg/dL	
TSH (ULTRASENSITIVE) METHOD: SANDWICH (ECLIA)	2.520	0.270 - 4.200	μIU/mL	

Interpretation(s)

End Of Report
Please visit www.srlworld.com for related Test Information for this accession

Meenahshi Malhotra

Ritu Pantay

Dr. Meenakshi Malhotra, MD Senior Consultant,48159 Dr. Ritu Pankaj, MD, PDCC Senior Consultant,30897





Page 20 Of 20

View Details

View Report



CLINICAL LABORATORY
Fortis Heart Institute & Multispeciality Hospital, Sector 62, Phase Viii, Mohali, 160062

Punjab, India

Tel: 0172-469-2222 Extn. 6726, 6727), 0172-469-2221 - CIN -

